heparin antagonist

WordNet

a polysaccharide produced in basophils (especially in the lung and liver) and that inhibits the activity of thrombin in coagulation of the blood; it (trade names Lipo-Hepin and Liquaemin) is used as an anticoagulant in the treatment of thrombosis and in heart surgery (同)Lipo-Hepin, Liquaemin
a drug that neutralizes or counteracts the effects of another drug
a muscle that relaxes while another contracts; "when bending the elbow the triceps are the antagonist"

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 静脈血栓塞栓症に対する低分子ヘパリン low molecular weight heparin for venous thromboembolic disease
2. ヘパリンおよび低分子ヘパリンの治療使用 therapeutic use of heparin and low molecular weight heparin
3. 妊娠中の抗凝固療法 anticoagulation during pregnancy
4. 外科患者における静脈血栓塞栓症の予防 prevention of venous thromboembolic disease in surgical patients
5. ヘパリン起因性血小板減少症 heparin induced thrombocytopenia

Northup PG, Caldwell SH.SourceDivision of Gastroenterology and Hepatology, Center for the Study of Coagulation in Liver Disease, University of Virginia, Charlottesville, Virginia. Electronic address: northup@virginia.edu.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.Clin Gastroenterol Hepatol.2013 Sep;11(9):1064-74. doi: 10.1016/j.cgh.2013.02.026. Epub 2013 Mar 16.
The human hemostasis system is complex and poorly understood after decades of intense scientific study. Despite multiple defects in routine coagulation laboratory studies in patients with chronic liver disease, there is growing evidence that these patients are effectively "rebalanced" with regard to
PMID 23506859

Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Siguret V, Gouin-Thibault I, Gaussem P, Pautas E.SourceUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France, virginie.siguret@parisdescartes.fr.
Drugs & aging.Drugs Aging.2013 Sep;30(9):687-99. doi: 10.1007/s40266-013-0101-0.
As longevity constantly increases, the number of elderly patients (75 years and older) who require anticoagulation likewise rises steadily. Managing elderly patients receiving anticoagulants is challenging because those patients are at high risk of both thrombosis and bleeding. Moreover, older pati
PMID 23884865

Perioperative management of patients who are receiving a novel oral anticoagulant.

Liew A, Douketis J.SourceDepartment of Medicine, McMaster University, Hamilton, ON, Canada, liew.aaron@gmail.com.
Internal and emergency medicine.Intern Emerg Med.2013 Sep;8(6):477-84. doi: 10.1007/s11739-013-0963-5. Epub 2013 Jun 27.
The use of novel oral anticoagulants (NOACs) is increasing since these drugs are at least as efficacious and safe as vitamin K antagonists (VKAs) for the management of patients with non-valvular atrial fibrillation and venous thromboembolism. Compared with VKAs, NOACs have a faster onset and offset
PMID 23807281

Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation　– Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging –